A pathological complete response after immunotherapy with pembrolizumab for distal duodenal adenocarcinoma caused by Lynch syndrome: a case report
Tóm tắt
Primary adenocarcinoma of the duodenum is a rare neoplasm that is often microsatellite instability-high (MSI-H). Pembrolizumab, a monoclonal antibody, has been recently approved in Japan for treatment of MSI-H solid tumors. Lynch syndrome is a frequent hereditary cancer predisposition syndrome. It is linked to an increased risk of various types of cancer, including colorectal and endometrial cancer, and is closely related to MSI-H. We present the case of a 55-year-old woman who was diagnosed with duodenal cancer. Biopsy findings revealed MSI-H, and pembrolizumab therapy was initiated because the tumor was in contact with the left renal vein and had metastasized to the mesenteric lymph nodes of the small intestine. Subsequently, after completing two courses of pembrolizumab therapy, the patient developed duodenal stenosis and underwent surgery. Pathological analysis of the resected specimen revealed no evidence of malignancy. Given the patient’s previous cancer history and the occurrence of cancer in close relatives, genetic testing of peripheral blood was performed, which revealed the diagnosis of Lynch syndrome. Furthermore, the variant responsible for Lynch syndrome was found to be a mutation of NM_000251.3:c.211 + 1G > C in MSH2.
Tài liệu tham khảo
Yasuda S, Harada S, Tsujimoto A et al (2019) A pathological complete response by chemotherapy with S-1 and oxaliplatin for a locally advanced duodenal adenocarcinoma in Lynch syndrome: a case report. Surg case Rep 5(1):146
Nishikawa Y, Hoshino N, Horimatsu T et al (2020) Chemotherapy for patients with unresectable or metastatic small bowel adenocarcinoma: a systematic review. Int J Clin Oncol 25(8):1441–1449
Hirashita T, Ohta M, Tada K et al (2018) Prognostic factors of non-ampullary duodenal adenocarcinoma. Jpn J Clin Oncol 48(8):743–747
Alicia L, Preethi S, Yelena K et al (2019) Microsatellite Instability Is Associated With the Presence of Lynch Syndrome Pan-Cancer. J Clin Oncol 37(4):286–295
Akagi K, Oki E, Taniguchi H et al (2021) Real-world data on microsatellite instability status in various unresectable or metastatic solid tumors. Cancer Sci 112(3):1105–1113
Maio M, Ascierto PA, Mnzyuk L et al (2022) Pembrolizumab in microsatellite instability high or mismatch repair deficient cancers: update analysis from the phase II KEYNOTE-158 study. Ann Oncol 33(9):929–938
Goldstein J, Tran B, Ensor J et al (2014) Multicenter retrospective analysis of metastatic colorectal cancer (CRC) with high-level microsatellite instability (MSI-H). Ann Oncol 25(5):1032–1038
Aurelien M, Dung T, Paolo AA et al (2020) Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study. J Clin Oncol 38(1):1–10
Laura LM, Anna JA, Jacov KB et al (2018) Outcomes and Treatment Options for Duodenal Adenocarcinoma: A Systematic Review and Meta-Analysis. Ann Surg Oncol 25(9):2681–2692
Jabbour SK, Mulvihill D (2014) Defining the role of adjuvant therapy: ampullary and duodenal adenocarcinoma. Semin Radiat Oncol 24(2):85–93
Kaklamanos IG, Bathe OF, Franceschi D et al (2000) Extent of resection in the management of duodenal adenocarcinoma. Am J Surg 179(1):37–41
Edwin OO, Sarah YB, Michael GS et al (2012) Neoadjuvant Treatment of Duodenal Adenocarcinoma: A Rescue Strategy. J Gastrointest Surg 16(2):320–324
Christina T, Lars HJ, Maria R et al (2021) An Update on Immune Checkpoint Therapy for the Treatment of Lynch Syndrome. Clin Exp Gastroenterol 14:181–197
Jan JK, Jan HK, Hans FA (2008) Small-bowel cancer in Lynch syndrome: is it time for surveillance? Lancet Oncol 9(9):901–905
Nassim H, Marion D, Stanislas C et al (2019) Duodenal tumor risk in Lynch syndrome. Dig Liver Dis 51(2):299–303
Naruse H, Ikawa N, Yamaguchi K et al (2009) Determination of splice-site mutation in Lynch syndrome (hereditary non-polyposis colorectal cancer) patients using functional splicing assay. Fam Cancer 8(4):509–517
Le DT, Uram JN, Wang H et al (2015) PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med 372:2509–2520
Jorg T, Sebastian S, Oliver H et al (2021) Complete Pathological Response After Neoadjuvant Short-Course Immunotherapy with Ipilimumab and Nivolumab in Locally Advanced MSI-H/dMMR Rectal Cancer. Oncologist 26(12):e2110–e2114